How were Epizyme's earnings last quarter?

Epizyme, Inc. (NASDAQ:EPZM) posted its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $0.16. The biopharmaceutical company had revenue of $5.20 million for the quarter, compared to analyst estimates of $8.65 million. Epizyme had a negative trailing twelve-month return on equity of 2,459.33% and a negative net margin of 391.90%. Epizyme's revenue for the quarter was up 45.8% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.55) EPS.

What other stocks do shareholders of Epizyme own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Epizyme investors own include Gilead Sciences (GILD) , Nektar Therapeutics (NKTR) , Pfizer (PFE) , Micron Technology (MU) , Novavax (NVAX) , CRISPR Therapeutics (CRSP) , Heron Therapeutics (HRTX) , TG Therapeutics (TGTX) , Advanced Micro Devices (AMD) and Dynavax Technologies (DVAX) .

NASDAQ:EPZM

Epizyme (EPZM) Stock Price, News & Analysis

→ A.I. “Perfect Storm” Could Send THESE Stocks Sky High (From InvestorPlace) (Ad)

Free EPZM Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $1.47
▼
$1.47
50-Day Range: $1.47
▼
$1.52
52-Week Range: $0.41
▼
$5.80

Volume: 7,960 shs
Average Volume: 3.23 million shs
Market Capitalization: $247.44 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Epizyme alerts:

Ad InvestorPlace

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

>>Check out what this A.I. Perfect Storm is<<

About Epizyme Stock (NASDAQ:EPZM)

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Ad InvestorPlace

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

>>Check out what this A.I. Perfect Storm is<<

EPZM Stock News Headlines

November 1, 2023 | morningstar.com

bluebird bio Inc BLUE

March 22, 2023 | thestreet.com

Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact

April 16, 2024 | Crypto Swap Profits (Ad)

Did You Get Your Free Bitcoin Yet?

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

August 12, 2022 | nasdaq.com

Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal - Nasdaq

August 12, 2022 | streetinsider.com

Form SC 14D9/A Epizyme, Inc. Filed by: Epizyme, Inc. - StreetInsider.com

August 10, 2022 | finance.yahoo.com

The past five years for Epizyme (NASDAQ:EPZM) investors has not been profitable

August 9, 2022 | benzinga.com

Epizyme: Q2 Earnings Insights - Benzinga

August 9, 2022 | businesswire.com

Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update - Business Wire

April 16, 2024 | Crypto Swap Profits (Ad)

Did You Get Your Free Bitcoin Yet?

August 9, 2022 | apnews.com

Epizyme: Q2 Earnings Snapshot

August 5, 2022 | seekingalpha.com

Ipsen extends tender offer date in Epizyme deal to get US antitrust clearance - Seeking Alpha

August 5, 2022 | businesswire.com

Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022 - Business Wire

July 28, 2022 | finance.yahoo.com

Ipsen Delivers Strong H1 2022 Results and Upgrades Its Full-Year Guidance - Yahoo Finance

July 26, 2022 | prnewswire.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ONEM, EPZM, LION - PR Newswire

July 16, 2022 | benzinga.com

Shareholder Alert - The M&A Class Action Firm Continues Investigating the Merger - FSTX, EPZM, STCN, SIMO - Benzinga

July 14, 2022 | prnewswire.com

SHAREHOLDER ALERT: Weiss Law Reminds RFP, ZEN, RDUS, and EPZM Shareholders About Its Ongoing Investigations - PR Newswire

July 14, 2022 | benzinga.com

EPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM - Benzinga

July 13, 2022 | streetinsider.com

Form SC 14D9 Epizyme, Inc. Filed by: Epizyme, Inc. - StreetInsider.com

July 11, 2022 | gurufocus.com

EPIZYME ALERT: Bragar Eagel & Squire, PC Investigates Merger of EPZM and Encourages Investors to Contact the Firm - GuruFocus.com

July 10, 2022 | globenewswire.com

INVESTIGATION NOTICE: Halper Sadeh LLP Investigates RFP, VIVO, RADA, EPZM - GlobeNewswire

July 6, 2022 | prnewswire.com

Moore Kuehn Encourages EPZM, RDUS, OBCI, and CNVY Investors to Contact Law Firm - PR Newswire

July 6, 2022 | seekingalpha.com

Epizyme Acquisition By Ipsen: CVR Value (NASDAQ:EPZM) - Seeking Alpha

July 5, 2022 | prnewswire.com

INVESTIGATION NOTICE: Halper Sadeh LLP Investigates ZEN, USAK, EPZM - PR Newswire

July 5, 2022 | marketscreener.com

Epizyme : Statement of Changes in Beneficial Ownership (Form 4) - Marketscreener.com

July 1, 2022 | streetinsider.com

EPIZYME ALERT: Bragar Eagel & Squire, PC Investigates Merger of EPZM and Encourages Investors to Contact the Firm - StreetInsider.com

July 1, 2022 | benzinga.com

EPIZYME ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of EPZM and Encourages Investors to Contact the Firm

June 29, 2022 | gurufocus.com

EPIZYME INVESTOR ALERT by the - GuruFocus.com

See More Headlines

Receive EPZM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Epizyme and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2021
Today: 4/16/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:EPZM
CUSIP: N/A
CIK: 1571498
Web: www.epizyme.com
Phone: (617) 229-5872
Fax: 617-349-0707
Employees: 250
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.72)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-251,120,000.00
Net Margins: -391.90%
Pretax Margin: -391.80%
Return on Equity: -2,459.33%
Return on Assets: -69.74%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.35
Quick Ratio: 5.19

Sales & Book Value

Annual Sales: $37.43 million
Price / Sales: 6.61
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.54) per share
Price / Book: -2.72

Miscellaneous

Outstanding Shares: 168,329,000
Free Float: 128,968,000
Market Cap: $247.44 million
Optionable: Optionable
Beta: -0.41

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. Grant C. Bogle (Age 64)
Pres, CEO, Principal Financial Officer & Director
Comp: $923.32k
Dr. Jeffery L. Kutok M.D. (Age 55)
Ph.D., Chief Scientific Officer
Comp: $646.13k
Dr. H. Robert Horvitz
Co-Founder & Chairman of the Scientific Advisory Board
Dr. Yi Zhang
Scientific Co-Founder & Member of The Scientific Advisory Board
Mr. Jerald Korn J.D. (Age 43)
Chief Operating Officer
Mr. Joseph Beaulieu (Age 41)
Sr. VP, Head of Fin., Controller, Treasurer & Principal Accounting Officer
Mr. Craig West CFA
VP of Investor Relations
Mr. John F. Weidenbruch (Age 61)
Sr. VP, Gen. Counsel & Sec.
Ms. Tanja Weber
Chief Bus. Officer
Dr. Mark A. De Rosch Ph.D. (Age 58)
Chief Regulatory Officer

Key Competitors

View All Competitors

EPZM Stock Analysis - Frequently Asked Questions

How were Epizyme's earnings last quarter?: Epizyme, Inc. (NASDAQ:EPZM) posted its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $0.16. The biopharmaceutical company had revenue of $5.20 million for the quarter, compared to analyst estimates of $8.65 million. Epizyme had a negative trailing twelve-month return on equity of 2,459.33% and a negative net margin of 391.90%. Epizyme's revenue for the quarter was up 45.8% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.55) EPS.
What other stocks do shareholders of Epizyme own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Epizyme investors own include Gilead Sciences (GILD), Nektar Therapeutics (NKTR), Pfizer (PFE), Micron Technology (MU), Novavax (NVAX), CRISPR Therapeutics (CRSP), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD) and Dynavax Technologies (DVAX).

This page (NASDAQ:EPZM) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Epizyme (EPZM) Stock Price, News & Analysis

About Epizyme Stock (NASDAQ:EPZM)

EPZM Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

EPZM Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info